Milovan Stankov Pugès, coronavirus hunter
At 36, he chairs NG Biotech, which has developed a rapid serological test to detect Covid-19. He faces multiple requests and doubles the size of his business, given the orders, including that expected this Monday from the Public Assistance-Hospitals of Paris.Pharmacy -
By Stanislas du Guerny
Posted on May 18, 2020 at 7:00 a.m.
To be wise ? Milovan Stankov Pugès knew how to keep it. At 36, the young CEO has demonstrated this in recent weeks. The name of his company, NG Biotech, circulated on news channels and was enthroned in the front page of the press: in April, the Ministry of the Armed Forces announced that it would support its serological tests with 1 million euros Covid-19 ultra-fast detection system. For its part, the Public Assistance-Hospitals of Paris would be on the verge of announcing this Monday a new purchase of these tests, supposed to reveal in about fifteen minutes, from a drop of blood, if a person is or has been in contact with the virus.
https://www.lesechos.fr/industrie-services/pharmacie-sante/milovan-stankov-puges-chasseur-de-coronavirus-1203704
Potential SP Valuation of AT1 - 80 cents to 1.30/share, page-394
-
- There are more pages in this discussion • 995 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 497908 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 67200 | 3 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable